Head to head

Peptide comparisons

The pairs people compare most, summarised from published research: how they work, what trials measured, reported side effects and approval status. Research use only — no dosing guidance.

Metabolic / Weight

Retatrutide vs Tirzepatide

Triple agonist versus dual agonist: what adding the glucagon receptor changes in the published data.

Read comparison →

Semaglutide vs Tirzepatide

The most-compared pair in metabolic research, including the first direct head-to-head obesity trial.

Read comparison →

Semaglutide vs Retatrutide

One receptor versus three: the established GLP-1 benchmark against the leading investigational triple agonist.

Read comparison →

Tissue Repair

BPC-157 vs TB-500

The two most-discussed repair peptides: how their proposed mechanisms differ and how thin the human data is.

Read comparison →

BPC-157 vs GHK-Cu

Injury-site repair research versus a copper tripeptide studied for collagen and skin remodelling.

Read comparison →

Growth Hormone

Sermorelin vs Tesamorelin

Two GHRH analogs on the same pituitary receptor, with very different regulatory histories.

Read comparison →

CJC-1295 DAC vs Ipamorelin

A long-acting GHRH analog versus a selective ghrelin-receptor agonist — two different routes to growth-hormone release.

Read comparison →

Cognitive

Semax vs Selank

Two Russian-developed regulatory peptides: one studied for neuroprotection, the other for anxiety.

Read comparison →

Other

PT-141 vs Melanotan II

A metabolite turned medicine versus its parent compound: same receptor family, different selectivity.

Read comparison →